About AbSci
AbSci is a company based in Vancouver (United States) founded in 2011. AbSci has raised $227.56 million across 7 funding rounds from investors including Fidelity Investments, AGC and KBI Biopharma. The company has 157 employees as of December 31, 2024. AbSci has completed 2 acquisitions, including Denovium and Totient. AbSci offers products and services including Drug Creation Platform and AI Target Discovery. AbSci operates in a competitive market with competitors including LabGenius, Ordaos, immunitoAI, Enpicom and Alkira Bio, among others.
- Headquarter Vancouver, United States
- Employees 157 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Absci Corporation
-
Annual Revenue
$4.53 M (USD)-20.71as on Dec 31, 2024
-
Net Profit
-$103.11 M (USD)6.75as on Dec 31, 2024
-
EBITDA
-$95.5 M (USD)-19.85as on Dec 31, 2024
-
Total Equity Funding
$227.56 M (USD)
in 7 rounds
-
Latest Funding Round
$125 M (USD), Series E
Mar 23, 2021
-
Investors
Fidelity Investments
& 15 more
-
Employee Count
157
as on Dec 31, 2024
-
Investments & Acquisitions
Denovium
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AbSci
AbSci is a publicly listed company on the NASDAQ with ticker symbol ABSI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AbSci
AbSci offers a comprehensive portfolio of products and services, including Drug Creation Platform and AI Target Discovery.
Integrates AI for biologics design and optimization in drug development.
Uses reverse immunology to find novel targets for antibody optimization.
People of AbSci
Unlock access to complete
Unlock access to complete
Funding Insights of AbSci
AbSci has successfully raised a total of $227.56M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $125 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AbSci
AbSci has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, AGC and KBI Biopharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Early-stage startups are invested in by sector-agnostic VC fund.
|
Locked | Locked | Locked | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked |
Investor details for AbSci
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AbSci
AbSci has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Denovium and Totient.
Investment portfolio details for AbSci
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI methods and solutions are provided to the biopharma industry.
|
Locked | Locked | 2018 | Locked | |
|
Developer of a drug discovery platform for cancer and autoimmune disease by using artificial intelligence
|
Locked | Locked | 2017 | Locked |
Complete acquisition details for AbSci
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - AbSci
Detailed financials for AbSci
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Absci Comparisons
Peer comparison for AbSci
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AbSci
AbSci operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as LabGenius, Ordaos, immunitoAI, Enpicom and Alkira Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven platform for discovering and optimizing therapeutic antibodies for treatments.
|
|
| Locked | Locked | Locked |
AI accelerator provided for biomedical research and drug discovery.
|
|
| Locked | Locked | Locked |
An AI-based platform for antibody discovery and therapeutics is developed.
|
|
| Locked | Locked | Locked |
Developer of bioinformatics platform integrating data, automation, and AI for biologics
|
|
| Locked | Locked | Locked |
Therapeutic antibodies targeting complex membrane proteins are developed.
|
Detailed competitors of AbSci
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Absci
Complete news archive for AbSci
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AbSci
AbSci was founded in 2011 and raised its 1st funding round 5 years after it was founded.
AbSci is headquartered in Vancouver, United States. It is registered at Vancouver, Washington, United States.
AbSci is a funded company, having raised a total of $227.56M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at AbSci is 157.
Annual revenue of AbSci is $4.53M as on Dec 31, 2024.
AbSci was founded in 2011 and is based in Vancouver, United States. An integrated platform is offered in the biotechnology sector, where biologic drug discovery and cell line development are combined into one process. Recombinant proteins for therapeutic uses are produced through AI-driven methods. This approach supports the generation of novel biologics, with operations centered on advancing protein engineering for medical applications.
AbSci's top competitors include Ordaos, immunitoAI and Enpicom.
AbSci offers Drug Creation Platform and AI Target Discovery.
Yes, AbSci is publicly traded on NASDAQ under the ticker symbol ABSI.
AbSci has 16 investors. Key investors include Fidelity Investments, AGC, KBI Biopharma, Perceptive Advisors, and ArrowMark Partners.
The ticker symbol of AbSci is ABSI on NASDAQ.